BioGenes and FyoniBio offer combined analytical services

Published: 25-Aug-2021

The companies say the agreement helps them ensure projects are handled with maximised efficiency

BioGenes and FyoniBio have signed an agreement to offer their pharmacokinetic and immuno-genicity services from a single source. These projects can be diverse and complex, involving work packages from antibody generation and production to the analysis of clinical samples with validated assays.

The companies say the agreement helps them ensure projects are handled with maximised efficiency. BioGenes, with expertise in in antibody production and ELISA setup, takes care of the first steps of the project, while FyoniBio, a specialist in bioassay development and validation for analysis of clinical samples, transfers the assay to the Meso Scale Discovery platform for analysing clinical samples under good clinical and laboratory practice. The Berlin-based companies say they guarantee comprehensive project management.

"We are very pleased that the cooperation with FyoniBio has now officially started," said Dr Alexander Knoll, CEO of BioGenes. "We are convinced that our complete package for high-quality and customised immunological tests for new biological compounds and clinical samples offers an enormous added value for customers."

"Both companies want to provide the perfect service for each customer. In this respect, as well as regarding scientific excellence in their respective fields, the two companies complement each other very well," said Dr Hans Baumeister, Service Division Manager at FyoniBio. "We are looking forward to the first joint projects.”

You may also like